A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Full Title
Medicinal preparations containing organic active ingredients > Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids > not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Filing statistics
CPC A61K 31/565 belongs to the parent subclass A61K, which recorded 1,717,491 patent applications worldwide between 2013 and 2023. Annual filings grew from 114,681 in 2013 to 125,843 in 2023 (+10%), peaking at 182,901 applications in 2016. The most active applicants in class A61 are PHILIPS ELECTRONICS (20,621 applications), NOVARTIS (15,792 applications) and ROCHE (14,303 applications).
Source: EPO PATSTAT, worldwide filings
3 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- A61K 31/566 having an oxo group in position 17, e.g. estrone
- A61K 31/567 substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/568 substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
Top Applicants
Top 10 applicants by patent filingsfor class A61, 2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 20,621
- NOVARTIS CH 15,792
- ROCHE CH 14,303
- COVIDIEN US 13,862
- HARVARD UNIVERSITY US 13,454
- UNIVERSITY OF CALIFORNIA US 12,798
- P&G (PROCTER & GAMBLE COMPANY) US 12,140
- L'OREAL FR 11,800
- OLYMPUS CORPORATION JP 9,894
- BOSTON SCIENTIFIC SCIMED US 9,513